

Introduction

The Global Lung Cancer Coalition (GLCC), an alliance of 41 patient organisations from 29 countries across the world, wanted to understand the challenges patients are currently facing to inform its patient advocacy work and the work of its member organisations.

In March 2024, the GLCC commissioned Censuswide to conduct a survey of lung cancer patients.

The survey received **905 responses** from patients across **18 countries**. For more information about the global findings, please visit www.lungcancercoalition.org/surveys.



Key findings from Mexico

Demographics

50

lung cancer patients responded



68% identified as male;
30% as female;
2% as non-binary



22% had non-small cell lung cancer

94%

were diagnosed in the last **five years**

Experiences of biomarker testing

83% of eligible respondents had been spoken to about biomarker testing



20% did not understand what biomarker testing was when they were first spoken to about it

These results suggest a clear need for **improved communication around the topic of biomarker testing**.

Support preferences in coping with lung cancer

76% get help from healthcare professionals; **66%** from family and friends; **24%** from social media communities




22% would like to get help through counselling/therapy, but only **12%** reported getting help that way

The respondents sought help from a variety of places. Their preferences largely matched where they were already getting help, except for a **greater need for counselling/therapy**.

Involvement with treatment teams

All respondents said that they felt **involved** in decisions about their treatment and care



68% of respondents felt **fully involved**, but **24%** wanted to be **more involved**

While patient involvement was high, **treatment teams need to ensure** patients have the opportunity to be **involved in decision-making as much as they would like** to be.

Preferred methods of receiving information

Throughout the patient journey, **face-to-face interactions** were preferred, especially for **regular check-ups** (preferred by 86%)



Print material was by far the most popular format for receiving information (**preferred by 60%**), followed by **cancer support hotlines (16%)**

Whilst the results indicate a **preference for direct interaction** when receiving information, it remains crucial that treatment teams **understand and accommodate individual patient preferences**.

Call to action

This year's Patient Experience Survey highlighted **encouraging trends, including high levels of involvement in treatment and care decisions**. The results, however, also showed that more needs to be done to ensure all patients feel as involved as they would like in decision-making, that treatment teams clearly communicate to patients on topics relevant to their condition, such as biomarker testing, and that patients can access the support options of their preference.

The GLCC is therefore calling for the **implementation of the rights set out in its Patient Charter in Mexico**, to ensure that all lung cancer patients have access to quality healthcare; informed self-determination, which includes involvement in decision-making; and physical and mental integrity.

More information

The GLCC members in Mexico are:

- **Respirando Con Valor:** <https://respirandoconvalor.org/>
- **Frente Unido por el Cáncer de Pulmón:** <https://frentepulmon.org/>



For more information about this survey and the work of the GLCC, please visit our website: <https://www.lungcancercoalition.org/> or email our secretariat at: glcc@roycastle.org